SMOFKABIVEN PERIPHERAL EMULSION FOR INFUSION

Indications

• Fluid and electrolyte imbalances
• Hypoglycemia
• Nutritional supplementation
• Diabetic emergencies

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing guidelines.

Adults: The dosage varies based on the clinical condition and specific formulation used. For intravenous administration, consult product literature for precise dosing.

Mechanism of action

Glucose supplies energy to tissues by undergoing glycolysis, which begins with its phosphorylation by hexokinase to form glucose 6-phosphate. This activates glucose for breakdown, ultimately generating ATP and NADH. The aerobic metabolism of glucose can yield up to 36 ATP molecules. Glucose also serves as a precursor for other biomolecules and regulates various physiological processes including gene transcription and hormone secretion.

Pharmacodynamics

Glucose is an obligatory energy source for cellular activities and plays a significant role in metabolic signaling. It is oxidized to yield energy through glycolysis, the citric acid cycle, and oxidative phosphorylation. Glucose can be converted into fat for energy storage and is stored as glycogen in the liver and muscles. Its administration increases blood glucose levels and stimulates insulin secretion, particularly through oral routes that activate gut incretin hormones.

Pharmacokinetics

Glucose is rapidly absorbed from the gastrointestinal tract or directly into the bloodstream when administered intravenously. It is distributed widely throughout the body and metabolized primarily in tissues requiring energy. The body maintains glucose homeostasis through regulatory mechanisms involving insulin and glucagon. Excess glucose can be stored as glycogen or converted to triglycerides for long-term energy storage.

Adverse effects

• Hyperglycemia
• Increased osmolarity
• Fluid overload
• Electrolyte imbalances

Interactions

• Insulin - may require dose adjustments

Precautions

• Use with caution in patients with diabetes mellitus
• Monitor blood glucose levels in patients receiving parenteral glucose
• Adjust dosage in renal impairment

Pregnancy

Glucose is generally considered safe in pregnancy; however, monitoring is advised, especially in diabetic patients.

Breast-feeding

Glucose is considered safe during breastfeeding, as it is a natural sugar found in breast milk.

Storage

Store at room temperature, away from light. Avoid freezing.

Formulations

• Glucose 5% solution for infusion
• Glucose 10% solution for infusion
• Glucose 0.9% solution for injection
• Glucose sodium chloride combination solutions

Indications

• Gastroesophageal reflux disease (GERD)
• Peptic ulcers
• Dyspepsia
• Acid-base balance disorders

Dosage

Children: Refer to specific acid formulations and guidelines for dosing. General dosing depends on the acid and its clinical use.

Adults: Refer to specific acid formulations and guidelines for dosing. General dosing depends on the acid and its clinical use.

Mechanism of action

Acids exert their effects primarily by dissociating into protons and anions in solution, thereby lowering the pH of the surrounding environment. This proton donation can influence various physiological processes, including enzyme activity, ion transport, and cellular signaling pathways. For example, hydrochloric acid in the stomach aids in digestion and the absorption of certain nutrients.

Pharmacodynamics

The pharmacodynamic effects of acids are largely dependent on their concentration and the specific type of acid involved. Weak acids may dissociate partially, leading to a less pronounced effect, while strong acids fully dissociate, leading to significant changes in pH and potential tissue irritation. Acids can also interact with various receptors and enzymes, influencing metabolic pathways and physiological responses.

Pharmacokinetics

The pharmacokinetics of acids vary widely depending on their chemical structure. Strong acids, such as hydrochloric acid, do not significantly enter systemic circulation due to their rapid dissociation in aqueous environments. Weak acids may be absorbed through the gastrointestinal tract, where their absorption is influenced by pH, solubility, and the presence of food. Metabolism and excretion pathways also vary, with some acids being metabolized to bicarbonate or other metabolites before excretion, primarily via the kidneys.

Adverse effects

• Gastrointestinal irritation
• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Electrolyte imbalance

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of gastrointestinal bleeding
• Consider potential interactions with other medications that may affect gastrointestinal motility or pH levels

Pregnancy

The safety of various acids during pregnancy may vary; consult specific guidelines for each acid. Generally, use should be limited to essential cases.

Breast-feeding

Caution is advised when using acids during breastfeeding; consult specific guidelines for each acid.

Storage

Store in a cool, dry place away from direct sunlight. Keep tightly closed and out of reach of children.

Indications

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Bronchospasm associated with respiratory conditions

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Aminophylline works as a phosphodiesterase inhibitor, leading to an increase in intracellular cyclic AMP (cAMP). This action results in the relaxation of bronchial smooth muscle, bronchodilation, and reduced airway resistance. It may also exert anti-inflammatory effects by inhibiting the release of inflammatory mediators from mast cells.

Pharmacodynamics

The pharmacodynamics of aminophylline involve its ability to enhance respiratory function by decreasing airway resistance, improving mucociliary clearance, and increasing respiratory muscle strength. Its therapeutic effects typically begin within 30 minutes of administration, with a peak effect occurring within 2 hours.

Pharmacokinetics

Aminophylline is rapidly absorbed following intravenous administration, with a bioavailability of approximately 100%. Its volume of distribution is large, indicating extensive tissue binding. The drug is metabolized primarily in the liver via cytochrome P450 enzymes, with a half-life ranging from 3 to 10 hours depending on patient factors, including age, liver function, and concurrent medications.

Interactions

• aminoglycosides+agalsidasealfa: Severe (decreases effects)
• aminoglycosides+agalsidasebeta: Severe (decreases effects)
• betablockers,selective+aminophylline: Severe (increases risk of bronchospasm)
• aminophylline+phosphodiesterasetype-: Severe (increases exposure)
• stiripentol+aminophylline: Severe (increases exposure)
• deferasirox+aminophylline: Severe (increases exposure)
• aminophylline+roflumilast: Severe (increases exposure)
• aciclovir+aminophylline: Moderate (increases exposure)
• aminophylline+macrolides: Moderate (decreases exposure)
• aminophylline+erythromycin: Moderate (decreases exposure)

Mechanism of action

Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into two main phases where the preparatory phase is initiated by the phosphorylation of glucose by hexokinase to form glucose 6-phosphate. The addition of the high-energy phosphate group activates glucose for the subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where the total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. These energy-producing reactions of glucose are limited to D-glucose as L-glucose cannot be phosphorylated by hexokinase. Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number, and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation to preserve cellular and whole body metabolic integrity. Vascular calcification is a hallmark of type 2 diabetes. Glucose stimulates calcification in culture of vascular smooth muscle cells (VSMCs) but the underlying mechanisms remain obscure. We observed that high glucose levels stimulated mouse and human VSMC trans-differentiation into chondrocytes, with increased levels of Sox9, type II collagen, glycosaminoglycan and Runx2 expression, and increased alkaline phosphatase activity and mineralization. These effects were associated with increased expression of IL-1beta, which stimulated alkaline phosphatase and calcification, suggesting that glucose induces chondrocyte differentiation of VSMCs, possibly through IL-1beta activation.

Pharmacodynamics

Blood glucose is an obligatory energy source for humans involved in various cellular activities, and it also acts as a signaling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water, and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation. Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen. Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.